Daptomycin-induced pulmonary infiltrates with eosinophilia

Shinde, Anita; Seifi, Ali; DelRe, Sallustio; Hussein, Wesam H. Moustafa; Ohebsion, Jonathan

doi:10.1016/j.jinf.2008.11.001

Cited by 21 publications

(10 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To our knowledge, only 4 prior reports have described druginduced pulmonary toxic effects related to daptomycin [1][2][3][4]. The first and third cases presented in our series meet all of the criteria proposed by Solomon and Schwartz for diagnosing drug-induced AEP.…”

Section: Discussionsupporting

confidence: 58%

Acute Eosinophilic Pneumonia Secondary to Daptomycin: A Report of Three Cases

et al. 2010

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 58%

Acute Eosinophilic Pneumonia Secondary to Daptomycin: A Report of Three Cases

et al. 2010

View full text Add to dashboard Cite

show abstract

“…In order to clarify the clinical characteristics of DAP-induced EP, we performed a literature review. Consequently, the data for 25 previous cases and the present case are summarized in the Table (8,(17)(18)(19)(20)(21)(22)(23)(24)(25)(26). The average age of the patients was 64 years (range: 26 to 87 years), and men were predominant (88%, 22 of 25 patients).…”

Section: Discussionmentioning

confidence: 86%

Myopathy and Eosinophilic Pneumonia Coincidentally Induced by Treatment with Daptomycin

et al. 2015

View full text Add to dashboard Cite

A 34-year-old man with 22q11.2 deletion syndrome (DiGeorge syndrome) concurrently suffered from myopathy and eosinophilic pneumonia shortly after receiving daptomycin (DAP) for right-sided infective endocarditis. The simultaneous occurrence of these phenomena in relation to DAP therapy has not been previously well described. An allergic reaction was suspected as a possible etiology of these DAP-related complications. This case highlights the need for close observation in order to detect both musculoskeletal and respiratory disorders from the start of DAP therapy. Physicians should pay more attention to this new drug, which is expected to be frequently used in various clinical settings.

show abstract

“…In contrast, there are an increasing number of case reports about acute eosinophilic pneumonia secondary to daptomycin, which is a diagnosis of exclusion [5][6][7][8][9][10][11]. It is characterized by rapid onset (usually \7 days), fever, hypoxemia, bilateral pulmonary infiltrates, and eosinophilia (typically [25%) in bronchoalveolar lavage fluid or on lung biopsy.…”

Section: Discussionmentioning

confidence: 99%

A rare cause of pulmonary infiltrates one should be aware of: a case of daptomycin-induced acute eosinophilic pneumonia

et al. 2011

View full text Add to dashboard Cite

We report a 69-year-old patient who developed fever and dyspnea 3 weeks after the initiation of daptomycin therapy for spondylodiscitis with lumbar epidural and bilateral psoas abscesses due to ampicillin- and high-level-gentamicin-resistant Enterococcus faecium. There was profound hypoxia and the chest X-ray showed extensive patchy infiltrates bilaterally. A bronchoalveolar lavage revealed 30% eosinophils and results of microbiological studies were normal. Daptomycin-induced eosinophilic pneumonia was diagnosed and the patient rapidly improved after the discontinuation of daptomycin and a brief course of prednisone. Increased attention must be paid to this rare but serious side effect of daptomycin.

show abstract

Daptomycin-induced pulmonary infiltrates with eosinophilia

Cited by 21 publications

References 2 publications

Acute Eosinophilic Pneumonia Secondary to Daptomycin: A Report of Three Cases

Acute Eosinophilic Pneumonia Secondary to Daptomycin: A Report of Three Cases

Myopathy and Eosinophilic Pneumonia Coincidentally Induced by Treatment with Daptomycin

A rare cause of pulmonary infiltrates one should be aware of: a case of daptomycin-induced acute eosinophilic pneumonia

Contact Info

Product

Resources

About